Critical component of the membrane-bound oxidase of phagocytes that generates superoxide. Associates with NOX3 to form a functional NADPH oxidase constitutively generating superoxide. Defects in CYBA are a cause of chronic granulomatous disease autosomal recessive cytochrome-b-negative (ARCGD). Chronic granulomatous disease is a genetically heterogeneous disorder characterized by the inability of neutrophils and phagocytes to kill microbes that they have ingested. Patients suffer from life-threatening bacterial/fungal infections. Belongs to the p22phox family. Note: This description may include information from UniProtKB.
Protein type: EC 1.-.-.-; Oxidoreductase; Membrane protein, integral
Molecular Function: electron carrier activity; heme binding; metal ion binding; protein binding; protein heterodimerization activity; SH3 domain binding; superoxide-generating NADPH oxidase activity
Biological Process: angiotensin-mediated regulation of glomerular filtration; antigen processing and presentation of exogenous peptide antigen via MHC class I; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; antigen processing and presentation of peptide antigen via MHC class I; cell redox homeostasis; cytochrome complex assembly; hydrogen peroxide biosynthetic process; inflammatory response; innate immune response; positive regulation of cell growth; positive regulation of endothelial cell proliferation; positive regulation of interleukin-6 production; positive regulation of phagocytosis; positive regulation of smooth muscle cell proliferation; positive regulation of superoxide release; positive regulation of toll-like receptor 2 signaling pathway; positive regulation of tumor necrosis factor production; regulation of release of sequestered calcium ion into cytosol; respiratory burst; response to drug; response to nutrient levels; small GTPase mediated signal transduction; smooth muscle hypertrophy; superoxide metabolic process; superoxide release; vascular endothelial growth factor receptor signaling pathway
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.